Recro Pharma, Inc. (REPH) Rating Increased to Hold at Zacks Investment Research
Recro Pharma, Inc. (NASDAQ:REPH) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Tuesday.
According to Zacks, “Recro Pharma, Inc. is a clinical stage specialty pharmaceutical company. It develops non-opioid therapeutics for the treatment of pain in the post-operative setting. The company is developing intranasal formulation of Dexmedetomidine (Dex) for the treatment of post-operative pain and cancer breakthrough pain; sublingual formulation of Dex for the treatment of chronic pain; and Fadolmidine (Fado), a product candidate to treat post-operative pain and neuropathic pain. Recro Pharma, Inc. is based in Malvern, Pennsylvania. “
Several other analysts have also issued reports on the company. Piper Jaffray Companies restated a “buy” rating and issued a $11.00 target price on shares of Recro Pharma in a research note on Friday. Roth Capital set a $20.00 target price on Recro Pharma and gave the company a “buy” rating in a research note on Monday, July 31st. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $12.63.
Recro Pharma (NASDAQ:REPH) opened at 8.64 on Tuesday. The firm’s market capitalization is $164.67 million. The firm has a 50-day moving average price of $8.65 and a 200-day moving average price of $7.78. Recro Pharma has a one year low of $5.81 and a one year high of $10.17.
Recro Pharma (NASDAQ:REPH) last issued its quarterly earnings results on Thursday, August 10th. The specialty pharmaceutical company reported ($0.48) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.54) by $0.06. The business had revenue of $16.93 million for the quarter, compared to analyst estimates of $14.90 million. Recro Pharma had a negative return on equity of 56.04% and a negative net margin of 46.75%. Analysts expect that Recro Pharma will post ($2.35) EPS for the current year.
TRADEMARK VIOLATION WARNING: “Recro Pharma, Inc. (REPH) Rating Increased to Hold at Zacks Investment Research” was posted by American Banking News and is the property of of American Banking News. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at https://www.americanbankingnews.com/2017/10/31/recro-pharma-inc-reph-rating-increased-to-hold-at-zacks-investment-research.html.
Institutional investors and hedge funds have recently modified their holdings of the business. Wells Fargo & Company MN raised its stake in shares of Recro Pharma by 3.0% in the first quarter. Wells Fargo & Company MN now owns 17,200 shares of the specialty pharmaceutical company’s stock valued at $150,000 after buying an additional 500 shares during the period. Bank of New York Mellon Corp bought a new stake in shares of Recro Pharma in the first quarter valued at $156,000. KCG Holdings Inc. bought a new stake in shares of Recro Pharma in the first quarter valued at $173,000. Rothschild Investment Corp IL bought a new stake in shares of Recro Pharma in the second quarter valued at $141,000. Finally, Janney Montgomery Scott LLC raised its stake in shares of Recro Pharma by 76.9% in the second quarter. Janney Montgomery Scott LLC now owns 22,085 shares of the specialty pharmaceutical company’s stock valued at $155,000 after buying an additional 9,600 shares during the period. Hedge funds and other institutional investors own 65.08% of the company’s stock.
Recro Pharma Company Profile
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Recro Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.